Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.47 |
| ▸ | F13A1 | P00488 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
| ▸ | TGM1 | P22735 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6489455 | 1.00 | MEN1 (0.60) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL2621369 | 0.88 | SMN1; SMN2 (0.58) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL2999166 | 0.88 | SMN1; SMN2 (0.58) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL2621342 | 0.88 | SMN1; SMN2 (0.58) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL2621378 | 0.87 | SMN1; SMN2 (0.61) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL70761 | 0.87 | SMN1; SMN2 (0.61) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL2621382 | 0.87 | SMN1; SMN2 (0.61) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL603957 | 0.87 | SMN1; SMN2 (0.61) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL70762 | 0.87 | SMN1; SMN2 (0.61) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL524450 | 0.86 | SMN1; SMN2 (0.61) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3324977-B1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-07-13 | — | — | EP | disclosed |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10865215-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200223867-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2020-07-16 | — | — | US | disclosed |
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2019067864-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
| US-9957281-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957281-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170022221-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2017-01-26 | — | — | US | disclosed |
| US-8822480-B2 | Bicyclic heterocycle derivatives and use thereof as GPR119 modulators | MERCK SHARP & DOHME CORP. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8815876-B2 | Bicyclic heterocycle derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815876-B2 | Bicyclic heterocycle derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20110212938-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | SCHERING CORPORATION | 2011-09-01 | — | — | US | disclosed |
| US-20110212938-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | SCHERING CORPORATION | 2011-09-01 | — | — | US | disclosed |
| US-20110166165-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | SCHERING CORPORATION (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166165-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | SCHERING CORPORATION (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166167-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166167-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2011-07-07 | — | — | US | disclosed |
| WO-2010009195-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | SCHERING CORPORATION (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166165-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | GPR119, GPR88, GCGR | MEN1 3901/4885KMT2A 3039/4885NPSR1 201/4885 |
| US-10865215-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | MEN1 3463/4885KMT2A 1493/4885NPSR1 114/4885 |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | SERPINB1, FURIN, HIF1AN | MEN1 3503/4885KMT2A 3794/4885NPSR1 1437/4885 |
| US-20110166167-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GCGR, GLP1R | MEN1 3614/4885KMT2A 3515/4885NPSR1 274/4885 |
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | MEN1 3463/4885KMT2A 1493/4885NPSR1 114/4885 |
| US-20170022221-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | MEN1 3463/4885KMT2A 1493/4885NPSR1 114/4885 |
| US-20200223867-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | MEN1 3463/4885KMT2A 1493/4885NPSR1 114/4885 |
| US-20110212938-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | GPR119, GPR88, GPR180 | MEN1 3778/4885KMT2A 3061/4885NPSR1 239/4885 |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | MEN1 3503/4885KMT2A 3794/4885NPSR1 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.